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Abstract Weight gain and metabolic changes have been
related to survival of early breast cancer patients (EBC).
‘’However, factors influencing metabolism post-diagnosis
are not fully understood. We measured anthropometric
[body mass index (BMI), body weight, waist and hip cir-
cumferences, and waist-to-hip ratio] and metabolic (levels
of insulin, glucose, H1Ac, total, HDL, and LDL choles-
terol, triglycerides, and the homeostasis model assessment
score [HOMA]) parameters in 433 pre- and post-meno-
pausal women with EBC at diagnosis and 3, 6, 9, 12, and
24 months thereafter. At diagnosis, compared with post-
menopausal women, pre-menopausal patients were more
likely to be leaner and to have a lower BMI, smaller waist
and hip circumferences, and waist-to-hip ratio. They had
also lower glucose, HbA1c, and triglyceride levels and a
lower HOMA score. Furthermore, they were more likely to
have an estrogen- and/or progesterone-positive tumor and a
higher proliferating breast cancer. During the first two post-
diagnosis years, all women showed a significant increase of
weight (?0.72 kg/year, P\ 0.001), waist circumference
(?1.53 cm/year, P\ 0.001), and plasma levels of LDL
cholesterol (?5.4 mg/dl per year, P = 0.045) and triglyc-
erides (?10.73 mg/dl per year, P = 0.017). In patients
receiving chemotherapy only, there was a significant
increase in hip circumference (?3.16 cm/year, P\ 0.001)
and plasma cholesterol levels (?21.26 mg/dl per year,
P\ 0.001). We showed that weight, body fat distribution,
and lipid profile changed in EBC patients receiving adju-
vant therapy. These changes occurred during the first 2
years after diagnosis and were not specifically related to
chemotherapy, menopausal status, or initial body weight.
Keywords Breast cancer  Body weight and
composition  Glucose and lipid metabolism  Menopausal
status  Adjuvant therapy
Introduction
Altered glucose metabolism and elevated body weight may
affect breast cancer (BC) prognosis [1]. Plasma cholesterol
levels may influence the risk of developing BC possibly
because cholesterol is a precursor of steroid hormones [2,
3], and endogenous sex steroid hormones stimulate cell
proliferation in BC [4]. Changes in metabolic parameters
related to body weight and glucose and lipid metabolism
have been observed after a BC diagnosis [5–9]. However,
data on how, when, and for how long these changes occur
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are far from being conclusive. Most studies are based on
retrospective chart review [7, 8, 10, 11], and body weight is
the only metabolic parameter evaluated. In other instances,
data were obtained during pretreatment and treatment but
not at diagnosis [12]. Importantly, only two studies
examined metabolic changes at prospectively established
time points and beyond one year of follow-up [9, 13].
To address these limitations and to investigate factors
potentially related to metabolic changes, we prospectively
evaluated body weight and fat composition, and the glu-
cose and lipid metabolism in women with early BC (EBC)
before adjuvant therapy, during treatment, and 2 years after
diagnosis.
Patients and methods
Study population
We enrolled women aged C18 years with histologically
confirmed BC treated with adjuvant chemotherapy and/or
hormonal therapy at the University of Naples Federico II
from July 2009 to October 2013. We excluded patients
with a confirmed diagnosis of type I or type II diabetes
based on laboratory data [21] and those taking medications
that could affect lipids or insulin and glucose levels. This
study was approved by the Ethics Committee of the
University Federico II (IRB approval number 343/15), and
the participants provided written informed consent to
participate.
Data retrieval
Demographics, tumor stage and size (T), nodal status (N),
estrogen receptor (ER), grading (G) progesterone receptor
(PR) and HER2/neu status, and tumor proliferation mea-
sured by ki67 labeling were collected. Body weight, height,
and waist and hip circumferences were measured before
treatment (baseline) and 3, 6, 9, 12, and 24 months there-
after. Waist and hip circumferences were measured as
previously described [14]. Body mass index (BMI) was
calculated as weight divided by height squared, and the
waist-to-hip ratio was calculated as waist circumference
divided by hip circumference.
Laboratory assays
Fasting glucose (mg/dl), serum insulin (lUI/ml), glycosy-
lated hemoglobin (HbA1c, %), total, HDL, and LDL
cholesterol (mg/dl), and triglycerides (mg/dl) were mea-
sured on venous blood collected at the time of diagnosis,
before cancer therapy (baseline). The homeostasis model
assessment (HOMA) index was calculated as glucose
(mg/dl) multiplied by insulin (lUI/ml) divided by 40.
Blood samples were collected in standardized conditions
after overnight fasting between 7 am and 10 am. All
measurements were repeated 3, 6, 9, 12, and 24 months
after baseline measurements.
Data analyses
Analyses were conducted in R version 3.0.1. Quantitative
variables were summarized with mean ± standard devia-
tion (SD); frequencies (percentage) were used for qualita-
tive variables. Anthropometric parameters (post-diagnosis
body weight, BMI, waist and hip circumferences, and
waist-to-hip ratio), blood metabolic profile (blood glucose,
serum insulin, HbA1c, total cholesterol, HDL cholesterol,
LDL cholesterol, and triglycerides), and tumor character-
istics (T, N, G, Ki67, ER, PgR, HER2, and treatment) were
compared at baseline between pre-menopausal and post-
menopausal patients with Student’s t test and Chi-square
test for numerical and categorical variables, respectively.
Non-parametric Spearman rho was used to assess correla-
tions among primary tumor characteristics and baseline
anthropometric and metabolic variables. To determine the
longitudinal variation of anthropometric and metabolic
parameters, we used a set of linear mixed models with
patient-level random effect for the intercept and with the
fixed effect of time coded continuously as the number of
years from diagnosis. The following fixed effects were
included: hormone receptor (HR) status, adjuvant treat-
ment, menopause status, T, N, HER-2, age, and BMI. In
each analysis, the significance of the interaction between
type of treatment and time was tested and, if significant, the
corresponding term was added to the model. The results of
linear mixed models are expressed as adjusted yearly
change in the corresponding outcome variable with 95 %
CI. A two-sided P\ 0.05 was considered statistically
significant.
Results
Demographic, clinical, and biological characteristics
A total of 433 EBC patients (175 pre-menopausal and 258
post-menopausal) were enrolled in the study. The patients’
baseline clinical and metabolic characteristics stratified for
menopausal status are summarized in Table 1. At diagnosis,
compared to post-menopausal patients, pre-menopausal
women were more likely to be leaner (mean body weight:
67.9 ± 13.2 vs. 71.6 ± 13.9 kg; P\ 0.001), to have a
lower BMI (26.3 ± 5 vs. 29.4 ± 5.8 kg/m2; P\ 0.001),
and to have a smaller waist circumference (87.3 ± 12.5 cm
vs. 94.8 ± 14.7 cm, P\ 0.001), hip circumference
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(100.6 ± 10.8 cm vs. 106.2 ± 11.7 cm, P\ 0.001), and
waist-to-hip ratio (0.87 ± 0.07 vs. 0.89 ± 0.09, P\ 0.001).
Unsurprisingly, post-menopausal patients were more likely
than pre-menopausal patients to have a lower glucose level
(92.22 ± 14.88 mg/dl vs. 104.78 ± 33.09 mg/dl:
P\ 0.001), lower HOMA index (2.46 ± 3.12 vs
3.29 ± 3.37, p = 0.006), lower HbA1c level (5.68 ± 2.62
vs. 6.16 ± 3.45; P = 0001), and a lower triglyceride level
(87.89 ± 42.46 mg/dl vs. 123.1 ± 68.45 mg/dl;
P\ 0.001). Insulin, cholesterol, HDL, and LDL levels were
unrelated to menopausal status.
Table 2 shows the baseline tumor characteristics strati-
fied for menopausal status in our patients. Pre-menopausal
women were more likely than post-menopausal women to
have a tumor that was ER positive (87.9 vs. 79.8 %;
P = 0.036), PR positive (85.5 vs. 76.7 %; P = 0.026), and
highly proliferating (mean ki67 32.2 ± 21.4 vs.
27.7 ± 19.9; P = 0.025). Nodal status, G, and HER 2
status were not related to menopausal status.
Adjuvant therapy differed significantly according to
menopausal status (P = 0.016). In detail, pre-menopausal
patients were more frequently treated with chemotherapy
followed by endocrine therapy (63.6 vs. 49.6 %) and less
frequently by chemotherapy alone (14.4 vs. 21.3 %) or
hormonal therapy alone (22.0 vs. 29.1 %). Most patients
(76 %), receiving chemotherapy alone, received combined
sequential treatment with anthracycline and cyclophos-
phamide for 4 cycles and weekly paclitaxel for 12 weeks.
All HER2-positive patients received trastuzumab for 18
consecutive cycles. Among post-menopausal patients, 22
(10.8 %), 82 (40.4 %), 35 (17.3 %), and 24 (11.8 %)
received 5 years of anastrozole, letrozole, exemestane, and
tamoxifen, and 13 (6.4 %), 17 (8.4 %), and 10 (4.9 %)
received tamoxifen for 2 years followed by anastrozole,
letrozole, and exemestane, respectively.
Mean change per year of anthropometric
and metabolic variables after adjuvant treatment
To characterize the pattern of anthropometric and meta-
bolic changes occurring during the 24 months after diag-
nosis, we used linear mixed models after removing the
effect of the following baseline variables: HR status, sys-
temic adjuvant treatment, menopause status, tumor size,
nodal status, HER-2, age, and BMI (Table 3). Over a
median follow-up of 14 months (range: 6 - 24 months),
there was a statistically significant increase in weight
(?0.72 kg/year, 95 % CI 0.32–1.11; P\ 0.001) and waist
circumference (?1.53 cm/year, 95 % CI 0.85–2.22;
P\ 0.001) in the overall population. In modeling hip cir-
cumference, there was a significant interaction effect
between time and treatment (F for interaction 3.723,
P = 0.025). In particular, only in patients receiving
chemotherapy alone there was a statistically significant
increase in hip circumference (?3.16 cm/year, 95 % CI
1.60–4.73; P\ 0.001). Among metabolic variables, there
were statistically significant increases in plasma levels of
LDL cholesterol (?5.4 mg/dl per year, 95 % CI
0.12–10.68; P = 0.045) and triglycerides (?10.73 mg/dl
per year, 95 % CI 1.95–19.51; P = 0.017) in all patients.
Cholesterol level was significantly increased in patients
receiving chemotherapy alone (?21.26 mg/dl per year,
95 % CI 10.18–32.35; P =\ 0.001) but not in the other
subgroups (F for interaction 4.03, P = 0.019). Lastly, no
statistically significant changes in glucose metabolism
markers, namely glucose and insulin levels and HbA1C
protein, were observed. Among post-menopausal patients,
women receiving hormonal therapy did not experience a
statistically significant change in weight, waist or hip cir-
cumferences, LDL cholesterol, triglycerides, and glucose
blood levels when compared to patients receiving
Table 1 Baseline patient
clinical and metabolic
characteristics stratified by
menopausal status
Pre-menopause (n = 173) Post-menopause (n = 258) p value
Age 42.5 ± 5.5 61.1 ± 6.8 \0.001
Body weight 67.9 ± 13.2 71.6 ± 13.9 0.004
Body mass index 26.3 ± 5 29.4 ± 5.8 \0.001
Waist circumference 87.3 ± 12.5 94.8 ± 14.7 \0.001
Hip circumference 100.6 ± 10.8 106.2 ± 11.7 \0.001
Waist-to-hip ratio 0.87 ± 0.07 0.89 ± 0.09 \0.001
Glucose 92.22 ± 14.88 104.78 ± 33.09 \0.001
Insulin 11.56 ± 13.89 12.78 ± 13.61 0.097
HOMA index 2.46 ± 3.12 3.29 ± 3.37 0.006
HbA1c 5.68 ± 2.62 6.16 ± 3.45 0.001
Total cholesterol 200.89 ± 38.57 208.22 ± 40.65 0.081
HDL cholesterol 61.26 ± 16.82 60.01 ± 18.46 0.388
LDL cholesterol 119.64 ± 37.07 126.84 ± 39.37 0.393
Triglycerides 87.89 ± 42.46 123.1 ± 68.45 \0.001
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chemotherapy only (data not shown). Importantly, in the
same patients’ group, there was not a statistically signifi-
cant change in the anthropometric or metabolic parameters
included in the study according to the type of hormonal
therapy (data not shown).
Discussion
In this study, we assessed metabolic changes occurring
after BC diagnosis and explored factors potentially impli-
cated in these variations. Our EBC patients gained weight
during the first 2 years after diagnosis, with an increase of
0.72 kg/year regardless of menopausal status, type of
adjuvant therapy delivered, body weight, or BMI at base-
line. Consistent with our findings, most previous studies
reported weight increase ranging from few grams to several
kgs (see Table S1, supplementary material) [5, 12, 13, 15–
23] after BC diagnosis. Some authors have suggested that
menopausal status influences the extent of weight gained
during adjuvant therapy. Two studies reported that weight
gain was more pronounced in pre-menopausal women than
in post-menopausal women [24, 25], thereby implicating
ovarian failure and menopause onset in weight variation
[15]. However, this finding is not confirmed by other
studies [10, 24, 26, 27]. We did not detect any difference in
the extent of weight increase in relation to menopausal
status or to age at diagnosis. The median age of our pre-
menopausal patients was 42 years, and it is possible that
the impact of treatment-related amenorrhea (due to
chemotherapy or ovarian function suppression) on body
weight may have been masked by a pretreatment peri-
menopausal hormone status in most of them. In a much
younger cohort of patients, the impact of drug-related
amenorrhea might have been more pronounced.
In previous studies [18, 19, 28], women gained more
weight with chemotherapy than with hormonal therapy or
radiotherapy. All our patients received adjuvant systemic
treatment and, importantly, weight gain was unrelated to
the type of systemic therapy delivered. The most frequent
hormonal agent given in earlier studies was tamoxifen [18,
19, 28]. Aromatase inhibitors for post-menopausal and
ovary suppression in addition to tamoxifen for pre-meno-
pausal women were the most frequently used hormonal
therapies in our patients (data not shown). We cannot
Table 2 Baseline tumor characteristics stratified by menopausal
status
Pre-
menopause
(n = 173)
Post-
menopause
(n = 258)
P value
Tumor size
Mean ± SD 21.6 ± 14.4 20.7 ± 11.8 0.862
\2 cm 93 (54.4) 136 (52.9) 0.766
C2 cm 78 (45.6) 121 (47.1)
Nodal status, n (%) 0.073
Negative 87 (50.9) 131 (52.4)
Positive 84 (49.1) 119 (47.6)
Grading, n (%) 0.745
G1 7 (4.1) 13 (5.1)
G2 57 (33.1) 90 (35.6)
G3 108 (62.8) 150 (59.3)
Ki67
Mean ± SD 32.2 ± 21.4 27.7 ± 19.9 0.025
B15 % 55 (33.1) 106 (42.7) 0.062
[15 % 111 (66.9) 142 (57.3)
ER 0.036
Negative 21 (12.1) 52 (20.2)
Positive 152 (87.9) 206 (79.8)
PgR 0.026
Negative 25 (14.5) 60 (23.3)
Positive 147 (85.5) 198 (76.7)
HER2 0.700
Negative 140 (81.4) 214 (82.9)
Positive 32 (18.6) 44 (17.1)
Treatment, n (%) 0.016
Chemotherapy only 25 (14.4) 55 (21.3)
Endocrine therapy only 38 (22.0) 75 (29.1)
Chemotherapy followed
by endocrine therapy
110 (63.6) 128 (49.6)
ER estrogen receptor, PgR progesterone receptor
Table 3 Mean change per year of metabolic variables adjusted for
hormone receptor status, systemic adjuvant treatment, menopause,
tumor dimension, nodal status, HER 2, age, and body mass index
Mean change/year 95 % CI P value
Body weight ?0.72 0.32 to 1.11 \0.001
Waist circumference ?1.53 0.85 to 2.22 \0.001
Hip circumference
CT ? OT ?0.82 -0.06 to 1.70 0.069
CT ?3.16 1.60 to 4.73 \0.001
OT ?0.72 -0.46 to 1.90 0.233
Glucose -0.83 -3.52 to 1.86 0.545
Insulin -0.55 -2.30 to 1.19 0.531
HbA1c -0.22 -0.63 to 0.20 0.301
Total cholesterol
CT ? OT ?3.82 -2.40 to 10.03 0.228
CT ?21.26 10.18 to 32.35 \0.001
OT ?2.07 -9.97 to 14.11 0.735
HDL cholesterol -1.93 -5.39 to 1.53 0.272
LDL cholesterol ?5.40 0.12 to 10.68 0.045
Triglycerides ?10.73 1.95 to 19.51 0.017
CT chemotherapy, OT endocrine therapy
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exclude that hormonal agents that have completely differ-
ent toxicity profiles affect differently the patient’s meta-
bolism and energy balance.
Our data show that weight increase is also associated to
changes of fat body composition, namely an increase of
waist circumference and hip circumference, especially in
patients who received chemotherapy. Waist and hip cir-
cumference and waist-to-hip ratio are additional measures
of body fat distribution and provide an index of both
subcutaneous and intra-abdominal adipose tissue [14].
Several studies reported a significant increase in fat mass
and a change in body fat distribution during chemotherapy
[29–32]. Interestingly, chemotherapy-induced weight gain
and changes in body composition seem to occur in specific
body zones, namely the legs, trunk, and arms, and lean
body mass losses affect predominantly the legs and lower
trunk [28, 33].
Our study confirms the occurrence of body composition
changes during and after adjuvant treatment, especially in
patients treated with chemotherapy alone [15, 29–32]. Of
note, our patients who received chemotherapy alone were
mostly treated with longer-lasting regimens containing
taxane and anthracyclines. It was suggested that
chemotherapy, particularly anthracyclines, may impair
muscle function by reducing mitochondrial respiratory
efficiency and cytosolic adenosine triphosphate content
[34], which can accentuate fatigue and inactivity, and
induce an increase of fat deposition in specific body areas
[34].
To our knowledge, ours is the first study to evaluate
whether serum metabolic biomarkers are compromised by
adjuvant treatment received after a diagnosis of BC. In our
patients, LDL cholesterol and triglyceride levels signifi-
cantly increased during the 2 years after treatment irre-
spective of the type of therapy delivered. Consequently,
this effect could be due to diet or lifestyle changes after BC
diagnosis rather than to a side-effect of treatment. In
patients treated with chemotherapy only, there was a
greater increase of total cholesterol, probably due to the
extensive use of anthracyclines in this subgroup. Adjuvant
therapy did not seem to affect glucose metabolism in our
patients.
A limitation of our study is the lack of a control arm
constituted by women receiving local therapy alone.
However, our analysis reflects current clinical practice
where it is highly unlikely for an EBC patient not to
receive systemic adjuvant therapy after local therapy, and
therefore our results are applicable to most patients. Fur-
thermore, a case–control study specifically addressing this
question is not realistic and, in any event, may not yield
information helpful for daily clinical practice. Furthermore,
we did not analyze other potential indicators of weight
gain, namely energy expenditure, dietary factors, change in
menopausal status or in sexual hormonal status during and
after systemic chemotherapy, and psychological factors.
Our cohort is relatively homogeneous in terms of race,
education, and social status (most patients were well edu-
cated and employed or retired); consequently, our results
may not be generalized to all EBC survivors in different
geographic areas.
In summary, we observed important alterations of
metabolism (increase in body weight, waist and hip cir-
cumferences, LDL, triglyceride, and total cholesterol
serum levels) in our patients receiving adjuvant therapy.
These alterations, regardless of the specific cause, persisted
up to 24 months after diagnosis and, as such, may be
responsible for the reduced survival of EBC patients.
Patients should be counseled about the risk of weight gain
and of an altered lipid profile after a BC diagnosis, and
should be aware that adjuvant hormonal therapy alone may
not necessarily prevent these metabolic alterations.
Preventive measures to reduce the risk of increasing weight
and to reduce or maintain a healthy lipid profile should be
offered to women who decide to undergo adjuvant sys-
temic treatment after a diagnosis of EBC and local
treatment.
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